{"id":470550,"date":"2025-12-25T10:19:19","date_gmt":"2025-12-25T10:19:19","guid":{"rendered":"https:\/\/www.europesays.com\/us\/470550\/"},"modified":"2025-12-25T10:19:19","modified_gmt":"2025-12-25T10:19:19","slug":"bristol-myers-bmy-offers-eliquis-free-to-medicaid-patients-under-new-pricing-pact","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/470550\/","title":{"rendered":"Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact"},"content":{"rendered":"\n

Bristol-Myers Squibb Company (NYSE:BMY<\/a>) is included among the Best Stocks for a Dividend Achievers List<\/strong><\/a>.<\/p>\n

\"Bristol-Myers Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact <\/p>\n

Several of the largest US and European drugmakers struck agreements with President Donald Trump on December 19 to voluntarily lower the prices of certain medicines. The move comes as the administration pushes to tie US drug prices more closely to lower costs overseas.<\/p>\n

Bristol-Myers Squibb Company (NYSE:BMY) was part of that group and one of the most notable commitments came from the company, as it said that it will provide Eliquis, its blockbuster blood thinner and most prescribed drug, free of charge to Medicaid patients. The agreement fits with the company\u2019s broader effort to improve cardiovascular care, expand patient access, and work with policymakers to reduce costs for Americans, without undercutting long-term innovation.<\/p>\n

A week earlier, on December 12, Morgan Stanley raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) to $37 from $36. The firm kept an Underweight rating on the stock. In its 2026 outlook note, the analyst said many of the policy concerns that weighed on biopharma stocks this year should start to fade in 2026. As that pressure eases, attention may shift back to company fundamentals. That\u2019s where stock selection could start to matter more again.<\/p>\n

Bristol-Myers Squibb Company (NYSE:BMY) operates globally and focuses on developing medicines for serious diseases. Its pipeline spans oncology, cardiovascular care, immunology, and other serious conditions.<\/p>\n

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/strong><\/a>.<\/p>\n

READ NEXT:\u00a012 Best Long Term US Stocks to Buy Now<\/a>\u00a0<\/b><\/strong>and\u00a013 Top Tech Stocks Paying Consistent Dividends<\/a><\/b><\/strong>.<\/p>\n

Disclosure: None.<\/p>\n","protected":false},"excerpt":{"rendered":"Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Achievers List. Bristol-Myers (BMY) Offers…\n","protected":false},"author":3,"featured_media":470551,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[213717,213719,213718,210,1060,5005,67,132,68],"class_list":{"0":"post-470550","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-bristol-myers-squibb-company","9":"tag-cardiovascular-care","10":"tag-dividend-achievers-list","11":"tag-health","12":"tag-medication","13":"tag-president-donald-trump","14":"tag-united-states","15":"tag-unitedstates","16":"tag-us"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/470550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=470550"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/470550\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/470551"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=470550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=470550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=470550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}